277 related articles for article (PubMed ID: 27561602)
1. Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Chem Biol Drug Des; 2017 Mar; 89(3):379-399. PubMed ID: 27561602
[TBL] [Abstract][Full Text] [Related]
2. Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen.
Coyne CP; Narayanan L
Curr Pharm Des; 2018; 24(11):1224-1240. PubMed ID: 29141539
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Drug Des Devel Ther; 2016; 10():2575-97. PubMed ID: 27574398
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine- (C
Coyne CP; Narayanan L
J Pharm Drug Deliv Res; 2015; 4(1):. PubMed ID: 26613088
[TBL] [Abstract][Full Text] [Related]
5. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).
Coyne CP; Narayanan L
Anticancer Agents Med Chem; 2019; 19(6):802-819. PubMed ID: 30514195
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.
Coyne CP; Jones T; Pharr T
Bioorg Med Chem; 2011 Jan; 19(1):67-76. PubMed ID: 21169024
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.
Coyne CP; Jones T; Bear R
J Cancer Ther; 2015 Jan; 6(1):62-89. PubMed ID: 25821636
[TBL] [Abstract][Full Text] [Related]
8. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Cancer Res Ther Oncol; 2014 Apr; 2(1):. PubMed ID: 25844392
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Clin Exp Oncol; 2013; 2(2):. PubMed ID: 26251840
[TBL] [Abstract][Full Text] [Related]
10. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src.
Manda S; Lee NK; Oh DC; Lee J
Molecules; 2020 Apr; 25(8):. PubMed ID: 32340152
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Cancer Ther; 2012 Oct; 3(5A):689-711. PubMed ID: 26225216
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.
Coyne CP; Jones T; Bear R
Cancer Biother Radiopharm; 2012 Feb; 27(1):41-55. PubMed ID: 22191802
[TBL] [Abstract][Full Text] [Related]
14. A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Holgersson G; Bergström S; Harmenberg J; Ringbom M; Klockare M; Jerling M; Ekman S; Lundström KL; Koyi H; Brandén E; Larsson O; Bergqvist M
Med Oncol; 2015 Apr; 32(4):129. PubMed ID: 25794491
[TBL] [Abstract][Full Text] [Related]
15. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
Coyne CP; Jones T; Bear R
Med Chem (Los Angeles); 2013 May; 3(2):210-223. PubMed ID: 26225219
[TBL] [Abstract][Full Text] [Related]
16. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
[TBL] [Abstract][Full Text] [Related]
17. Mebendazole in simultaneous combination with dexamethasone-(C
Coyne CP; Narayanan L
J Exp Ther Oncol; 2019 Dec; 13(2):81-118. PubMed ID: 31881126
[TBL] [Abstract][Full Text] [Related]
18. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
19. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
[TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
